These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 2009437)

  • 21. Etiologic factors and clinical features of symptomatic epilepsy: focus on pediatric cases.
    Fujiwara T; Shigematsu H
    Psychiatry Clin Neurosci; 2004 Jun; 58(3):S9-S12. PubMed ID: 15149308
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antiepileptic drug resistance and tolerance in epilepsy.
    Widdess-Walsh P; Devinsky O
    Rev Neurol Dis; 2007; 4(4):194-202. PubMed ID: 18195671
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Is tolerance to antiepileptic drugs clinically relevant?
    Avanzini G
    Epilepsia; 2006 Aug; 47(8):1285-7. PubMed ID: 16922871
    [No Abstract]   [Full Text] [Related]  

  • 24. Visit management: reducing unnecessary paperwork.
    Salzmann JK
    Epilepsy Res Suppl; 1993; 10():223-31. PubMed ID: 8251100
    [No Abstract]   [Full Text] [Related]  

  • 25. Handling seizure data: special problems.
    Pierce MW; Shu VS
    Epilepsy Res Suppl; 1993; 10():175-8. PubMed ID: 8251093
    [No Abstract]   [Full Text] [Related]  

  • 26. Therapeutic strategies in the choice of antiepileptic drugs.
    de Borchgrave V; Delvaux V; de Tourchaninoff M; Dubru JM; Ghariani S; Grisar T; Legros B; Ossemann M; Sadzot B; Tugendhaft P; Van Bogaert P; van Rijckevorsel K;
    Acta Neurol Belg; 2002 Mar; 102(1):6-10. PubMed ID: 12094563
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Angels and demons: neurotrophic factors and epilepsy.
    Simonato M; Tongiorgi E; Kokaia M
    Trends Pharmacol Sci; 2006 Dec; 27(12):631-8. PubMed ID: 17055067
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacoresistance.
    Potschka H; Brodie MJ
    Handb Clin Neurol; 2012; 108():741-57. PubMed ID: 22939063
    [No Abstract]   [Full Text] [Related]  

  • 29. Determinants of drug brain uptake in a rat model of seizure-associated malformations of cortical development.
    Marchi N; Guiso G; Caccia S; Rizzi M; Gagliardi B; Noé F; Ravizza T; Bassanini S; Chimenti S; Battaglia G; Vezzani A
    Neurobiol Dis; 2006 Dec; 24(3):429-42. PubMed ID: 17027274
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Blood-brain barrier dysfunction, seizures and epilepsy.
    van Vliet EA; Aronica E; Gorter JA
    Semin Cell Dev Biol; 2015 Feb; 38():26-34. PubMed ID: 25444846
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antiepileptic drugs: future development.
    Porter RJ
    Epilepsy Res Suppl; 1993; 10():69-77. PubMed ID: 7504494
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prediction of potential positive drug interactions.
    Nemire RE; Wauquier A
    Epilepsy Res Suppl; 1996; 11():245-52. PubMed ID: 9294742
    [No Abstract]   [Full Text] [Related]  

  • 33. Positive impact of omega-3 fatty acid supplementation in a dog with drug-resistant epilepsy: a case study.
    Scorza FA; Cavalheiro EA; Arida RM; Terra VC; Scorza CA; Ribeiro MO; Cysneiros RM
    Epilepsy Behav; 2009 Aug; 15(4):527-8. PubMed ID: 19541544
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Breaking Bad: the Structure and Function of the Blood-Brain Barrier in Epilepsy.
    Han H; Mann A; Ekstein D; Eyal S
    AAPS J; 2017 Jul; 19(4):973-988. PubMed ID: 28550637
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Rufinamide (Banzel) for epilepsy.
    Med Lett Drugs Ther; 2009 Mar; 51(1307):18-20. PubMed ID: 19265777
    [No Abstract]   [Full Text] [Related]  

  • 36. Clinical trials performed for the new drug approval process in the United States: standard methods and alternative methods.
    Browne TR
    Epilepsy Res Suppl; 1993; 10():31-44. PubMed ID: 8251105
    [No Abstract]   [Full Text] [Related]  

  • 37. [Drug-resistant epilepsy].
    Nakken KO; Taubøll E
    Tidsskr Nor Laegeforen; 2009 Oct; 129(19):1986-9. PubMed ID: 19823202
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Patient recruitment and compliance issues in clinical trials.
    Cramer JA
    Epilepsy Res Suppl; 1993; 10():211-22. PubMed ID: 8251099
    [No Abstract]   [Full Text] [Related]  

  • 39. Postictal blood-brain barrier breakdown on contrast-enhanced MRI.
    Alvarez V; Maeder P; Rossetti AO
    Epilepsy Behav; 2010 Feb; 17(2):302-3. PubMed ID: 20097615
    [No Abstract]   [Full Text] [Related]  

  • 40. Epilepsy resistant to anticonvulsant therapy.
    Hass JA; Fenner WR
    Probl Vet Med; 1989; 1(4):596-605. PubMed ID: 2520136
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.